Takeda Gives Sun Pharma, Cipla Rights to Commercialise Gastro Drug in India

Gastroesophageal reflux disease (GERD) affects 5% to 28.5% of India’s population. Takeda has granted both drugmakers non-exclusive patent licensing rights for the drug Japan’s Takeda Pharmaceutical gave India’s Sun Pharmaceutical and Cipla the rights to commercialize gastrointestinal drug Vonoprazan in the country. The drug, which is sold in the form of tablets under the brand…

Read More

Income Tax Exemption vs Rebate vs Deductions: Budget 2024 May Exempt Income Up to Rs 5 Lakh

As the Budget for the financial year 2024-25 approaches, there are reports that the government might raise the income tax exemption limit to Rs 5 lakh. Here’s a detailed difference between income tax exemption, rebate and deductions, and their implications. As the Budget for the financial year 2024-25 approaches, there are reports that the government…

Read More